CStone Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer
Sugemalimab is the world’s first anti-PD-L1 monoclonal antibody approved for the treatment of gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
This marks the 13th NDA approval obtained by CStone and sugemalimab&… อ่านเพิ่ม